Allos Therapeutics Announces Dismissal of Securities Class Action Lawsuit
22 10월 2005 - 1:02AM
PR Newswire (US)
WESTMINSTER, Colo., Oct. 21 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that the only
remaining securities class action lawsuit that had been brought
against the company and one of its officers in May 2004 has been
dismissed with prejudice. In an opinion dated October 20, 2005, the
United States District Court for the District of Colorado concluded
that the plaintiff's complaint failed to meet the legal pleading
requirements applicable to its alleged claims. The plaintiff has 30
days to determine whether it will appeal the decision to the U.S.
Court of Appeals for the Tenth Circuit. "We are extremely pleased
with the result," said Marc H. Graboyes, Vice President, General
Counsel of Allos. "We have always believed that the plaintiff's
case lacked merit, and we are gratified that the court agreed. We
are excited to put this behind us and continue moving forward with
our on-going clinical trials and product development efforts."
About Allos Therapeutics, Inc. Allos Therapeutics, Inc.
(NASDAQ:ALTH) is a biopharmaceutical company focused on developing
and commercializing innovative small molecule therapeutics for the
treatment of cancer. Allos' lead product candidate, EFAPROXYN, is a
synthetic small molecule designed to sensitize hypoxic, or
oxygen-deprived, tumor tissue during radiation therapy. EFAPROXYN
is currently being evaluated as an adjunct to whole brain radiation
therapy in a pivotal Phase 3 trial in women with brain metastases
originating from breast cancer. Allos' other product candidates
are: PDX (pralatrexate), a small molecule chemotherapeutic agent
(DHFR inhibitor) currently under investigation as both a single
agent and in combination therapy regimens in patients with
non-small cell lung cancer and Non-Hodgkin's lymphoma; and RH1, a
small molecule chemotherapeutic agent bioactivated by the enzyme
DT-diaphorase currently under evaluation in patients with advanced
solid tumors. For more information, visit the Company's web site at
http://www.allos.com/. DATASOURCE: Allos Therapeutics, Inc.
CONTACT: Jennifer Neiman, Manager, Corporate Communications of
Allos Therapeutics, Inc., +1-720-540-5227, Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles